MONROVIA, Calif.--(BUSINESS WIRE)--Apr. 1, 2019--
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company
developing engineered monoclonal antibodies for the treatment of cancer,
autoimmune disease, asthma and allergic diseases, today announced that
company management will participate in two upcoming conferences:
- Jefferies 6th Annual IO Cell Therapy Summit
Friday, April 5, 2019
Location: Boston, MA
- 18th Annual Needham Healthcare Conference
Tuesday, April 9, 2019
Presentation Time: 2:10 p.m. ET
New York, NY
A live webcast of the Needham Healthcare Conference presentation will be
available under "Events & Presentations" in the Investors section of the
Company's website located at https://investors.xencor.com/events.cfm.
A replay of the event will be posted on the Xencor website approximately
one hour after the live event and will be available for 90 days
following the event.
About Xencor, Inc.
Xencor is a clinical-stage biopharmaceutical company developing
engineered monoclonal antibodies for the treatment of cancer, autoimmune
disease, asthma and allergic diseases. Currently, 12 candidates
engineered with Xencor's XmAb® technology are in
clinical development internally and with partners. Xencor's XmAb
antibody engineering technology enables small changes to the structure
of monoclonal antibodies resulting in new mechanisms of therapeutic
action. For more information, please visit www.xencor.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190401005858/en/
Source: Xencor, Inc.
Jason I. Spark